Overactive bladder syndrome: Is a request for a dose increase indicative of more severe symptoms? Results from a randomised, double-blind, placebo-controlled, risfng-dose study of solifenacin (SUNRISE)

Cardozo L. , Avdoshin V. , Wolski Z. , Pavlik I. , Sofras F.E. , Toth Z. , Vasco P.M. , Drogendijk T. , Wright D.M. , Bolodeoku J.

INTERNATIONAL UROGYNECOLOGY JOURNAL

SPRINGER LONDON LTD

Английский

Опубликовано

18

2007